Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

MRKMerck Sharp & Dohme LLCSigning up patients

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

Ovarian Cancer Recurrent

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 5 insiders sold shares within a month

    Since Aug 13, 2026 · was worth 5, fading over time

    +1.9
Worry score2

Score over time

Stage
Phase 1/2
Patients
605 (planned)
Started
Apr 15, 2025
Main results expected
Mar 27, 2029
Fully finished
Feb 7, 2031
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)

    Measured over: Up to 21 days

  • Part 1: Number of Participants with One or More Adverse Events (AEs)

    Measured over: Up to approximately 3 years

  • Part 1: Number of Participants who Discontinue Study Intervention Due to an AE

    Measured over: Up to approximately 3 years

  • Part 2: Objective Response Rate (ORR)

    Measured over: Up to approximately 3 years

  • Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2

    Measured over: Up to approximately 3 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT06843447 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06843447) ↗